 Terry Fry
Concepts (435)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 31 | 2023 | 191 | 7.870 |
Why?
| | T-Lymphocytes | 47 | 2023 | 1774 | 5.930 |
Why?
| | Antigens, CD19 | 22 | 2022 | 96 | 4.560 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 65 | 4.460 |
Why?
| | Graft vs Host Disease | 20 | 2023 | 216 | 4.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 26 | 2023 | 540 | 3.410 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2023 | 267 | 3.260 |
Why?
| | Receptors, Antigen, T-Cell | 16 | 2023 | 632 | 3.110 |
Why?
| | CD8-Positive T-Lymphocytes | 17 | 2023 | 702 | 2.930 |
Why?
| | Immunotherapy | 14 | 2023 | 493 | 2.910 |
Why?
| | Dendritic Cells | 11 | 2016 | 442 | 2.720 |
Why?
| | Cancer Vaccines | 9 | 2018 | 139 | 2.180 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2023 | 984 | 2.080 |
Why?
| | Hematologic Neoplasms | 8 | 2023 | 133 | 2.050 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 8 | 2022 | 11 | 1.920 |
Why?
| | Interleukin-7 | 18 | 2012 | 44 | 1.870 |
Why?
| | Lymphoma, B-Cell | 6 | 2022 | 85 | 1.610 |
Why?
| | Bone Marrow Transplantation | 9 | 2023 | 244 | 1.440 |
Why?
| | Lymphocyte Transfusion | 4 | 2017 | 19 | 1.400 |
Why?
| | Leukemia, Myeloid, Acute | 5 | 2023 | 532 | 1.370 |
Why?
| | Adoptive Transfer | 10 | 2019 | 204 | 1.300 |
Why?
| | Graft vs Leukemia Effect | 4 | 2017 | 12 | 1.130 |
Why?
| | Neoplasms | 13 | 2023 | 2179 | 1.090 |
Why?
| | Cytokines | 12 | 2022 | 1900 | 1.060 |
Why?
| | Antigens, Neoplasm | 5 | 2019 | 228 | 1.040 |
Why?
| | Dipeptides | 3 | 2014 | 51 | 1.040 |
Why?
| | H-Y Antigen | 5 | 2013 | 9 | 1.020 |
Why?
| | Graft vs Tumor Effect | 3 | 2021 | 8 | 0.930 |
Why?
| | Mice | 37 | 2023 | 15520 | 0.840 |
Why?
| | Tumor Escape | 3 | 2021 | 38 | 0.840 |
Why?
| | Animals | 51 | 2023 | 33381 | 0.830 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 8 | 0.830 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 180 | 0.800 |
Why?
| | Immune System | 5 | 2010 | 181 | 0.780 |
Why?
| | Perforin | 1 | 2020 | 19 | 0.780 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2018 | 33 | 0.770 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 23 | 0.750 |
Why?
| | Retinoblastoma | 1 | 2020 | 28 | 0.750 |
Why?
| | WT1 Proteins | 2 | 2018 | 12 | 0.750 |
Why?
| | Lymphoma | 2 | 2019 | 180 | 0.730 |
Why?
| | Myelodysplastic Syndromes | 5 | 2023 | 119 | 0.720 |
Why?
| | Humans | 97 | 2023 | 118972 | 0.710 |
Why?
| | Erythropoietin | 1 | 2020 | 82 | 0.700 |
Why?
| | Adjuvants, Immunologic | 4 | 2014 | 207 | 0.700 |
Why?
| | T-Lymphocyte Subsets | 6 | 2023 | 396 | 0.690 |
Why?
| | Transplantation, Homologous | 9 | 2018 | 415 | 0.690 |
Why?
| | Recurrence | 12 | 2023 | 975 | 0.680 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 158 | 0.670 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 4908 | 0.670 |
Why?
| | Allergy and Immunology | 1 | 2019 | 57 | 0.650 |
Why?
| | Boron Compounds | 2 | 2014 | 18 | 0.590 |
Why?
| | Genetic Engineering | 2 | 2019 | 83 | 0.590 |
Why?
| | Hematopoietic Stem Cells | 4 | 2016 | 359 | 0.580 |
Why?
| | Calcitonin | 1 | 2016 | 29 | 0.580 |
Why?
| | Child | 34 | 2023 | 19129 | 0.580 |
Why?
| | Cell Lineage | 2 | 2016 | 318 | 0.570 |
Why?
| | Cell Plasticity | 1 | 2016 | 24 | 0.560 |
Why?
| | Disease Models, Animal | 7 | 2020 | 3730 | 0.550 |
Why?
| | Antigens, CD | 2 | 2017 | 460 | 0.550 |
Why?
| | Leukemia | 4 | 2023 | 208 | 0.550 |
Why?
| | Leukapheresis | 2 | 2017 | 27 | 0.540 |
Why?
| | Lymphocyte Activation | 11 | 2021 | 1067 | 0.540 |
Why?
| | Receptors, Cytokine | 1 | 2015 | 33 | 0.530 |
Why?
| | Donor Selection | 1 | 2015 | 73 | 0.520 |
Why?
| | Mice, Knockout | 7 | 2020 | 2680 | 0.510 |
Why?
| | Cell Line, Tumor | 12 | 2021 | 2851 | 0.490 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 69 | 0.490 |
Why?
| | Photopheresis | 2 | 2011 | 9 | 0.490 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 44 | 0.490 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 200 | 0.480 |
Why?
| | Rhabdomyosarcoma | 2 | 2014 | 57 | 0.480 |
Why?
| | Vaccination | 2 | 2012 | 1222 | 0.460 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2012 | 16 | 0.450 |
Why?
| | Boronic Acids | 1 | 2013 | 35 | 0.450 |
Why?
| | Recombinant Fusion Proteins | 4 | 2017 | 653 | 0.450 |
Why?
| | Apoptosis | 7 | 2019 | 2484 | 0.450 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 189 | 0.440 |
Why?
| | Female | 46 | 2021 | 61564 | 0.430 |
Why?
| | Flow Cytometry | 6 | 2020 | 1085 | 0.430 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 401 | 0.420 |
Why?
| | Adult | 29 | 2023 | 31512 | 0.420 |
Why?
| | Homeostasis | 4 | 2006 | 594 | 0.420 |
Why?
| | Antigens, CD34 | 2 | 2011 | 98 | 0.410 |
Why?
| | Siblings | 4 | 2014 | 235 | 0.410 |
Why?
| | Mice, Inbred C3H | 4 | 2014 | 250 | 0.410 |
Why?
| | Young Adult | 17 | 2023 | 10793 | 0.410 |
Why?
| | Neoplasm, Residual | 3 | 2020 | 103 | 0.400 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 28 | 0.390 |
Why?
| | Lymphocyte Depletion | 7 | 2014 | 119 | 0.390 |
Why?
| | Neoplasm Metastasis | 3 | 2016 | 544 | 0.390 |
Why?
| | Antigen Presentation | 2 | 2009 | 194 | 0.390 |
Why?
| | Living Donors | 3 | 2014 | 319 | 0.380 |
Why?
| | Adolescent | 22 | 2023 | 18480 | 0.370 |
Why?
| | Male | 38 | 2021 | 57801 | 0.370 |
Why?
| | Immunologic Memory | 7 | 2016 | 313 | 0.360 |
Why?
| | Transplantation Conditioning | 4 | 2018 | 156 | 0.360 |
Why?
| | Signal Transduction | 6 | 2019 | 4709 | 0.350 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2009 | 211 | 0.350 |
Why?
| | Sarcoma, Ewing | 2 | 2012 | 65 | 0.340 |
Why?
| | Gene Expression | 5 | 2020 | 1489 | 0.340 |
Why?
| | Receptors, Interferon | 1 | 2009 | 49 | 0.340 |
Why?
| | Interleukin-10 | 1 | 2011 | 306 | 0.330 |
Why?
| | Child, Preschool | 15 | 2023 | 9491 | 0.330 |
Why?
| | Thymus Gland | 3 | 2004 | 300 | 0.330 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 969 | 0.320 |
Why?
| | Remission Induction | 4 | 2017 | 247 | 0.320 |
Why?
| | Mutation | 2 | 2015 | 3457 | 0.320 |
Why?
| | Monocytes | 1 | 2011 | 513 | 0.310 |
Why?
| | Social Adjustment | 1 | 2008 | 56 | 0.310 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 381 | 0.310 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2019 | 671 | 0.300 |
Why?
| | Carcinoma | 1 | 2009 | 204 | 0.300 |
Why?
| | Receptors, Antigen | 2 | 2017 | 11 | 0.290 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 245 | 0.290 |
Why?
| | Allografts | 3 | 2018 | 135 | 0.290 |
Why?
| | Neuroblastoma | 2 | 2021 | 135 | 0.290 |
Why?
| | Lymphopoiesis | 2 | 2006 | 23 | 0.280 |
Why?
| | Prognosis | 7 | 2020 | 3443 | 0.280 |
Why?
| | Models, Immunological | 3 | 2020 | 94 | 0.270 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 900 | 0.270 |
Why?
| | Tissue Donors | 4 | 2018 | 336 | 0.270 |
Why?
| | Interferon-gamma | 1 | 2009 | 736 | 0.260 |
Why?
| | Disease Progression | 5 | 2021 | 2490 | 0.260 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 153 | 0.260 |
Why?
| | Receptors, Interleukin-7 | 3 | 2011 | 26 | 0.260 |
Why?
| | Mice, Transgenic | 6 | 2021 | 2025 | 0.260 |
Why?
| | Immunocompromised Host | 2 | 2010 | 200 | 0.260 |
Why?
| | Transplantation, Autologous | 5 | 2018 | 191 | 0.250 |
Why?
| | Unrelated Donors | 3 | 2023 | 38 | 0.250 |
Why?
| | Lentivirus | 3 | 2019 | 52 | 0.240 |
Why?
| | Macrophages | 1 | 2011 | 1324 | 0.230 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 19 | 0.230 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2017 | 359 | 0.230 |
Why?
| | Interleukin-15 | 4 | 2014 | 77 | 0.230 |
Why?
| | Treatment Outcome | 11 | 2021 | 9342 | 0.230 |
Why?
| | Regeneration | 2 | 2004 | 165 | 0.230 |
Why?
| | Combined Modality Therapy | 4 | 2021 | 1166 | 0.230 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 42 | 0.220 |
Why?
| | Genetic Vectors | 3 | 2019 | 302 | 0.220 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 156 | 0.210 |
Why?
| | Mice, SCID | 4 | 2019 | 333 | 0.210 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 53 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 740 | 0.210 |
Why?
| | Gangliosides | 1 | 2021 | 19 | 0.200 |
Why?
| | Lymphopenia | 4 | 2011 | 48 | 0.200 |
Why?
| | Anxiety | 1 | 2008 | 845 | 0.200 |
Why?
| | Coculture Techniques | 2 | 2012 | 208 | 0.200 |
Why?
| | Thrombocytopenia | 1 | 2023 | 185 | 0.200 |
Why?
| | Bone Marrow | 3 | 2020 | 255 | 0.200 |
Why?
| | Recovery of Function | 1 | 2005 | 604 | 0.190 |
Why?
| | Capillary Leak Syndrome | 1 | 2020 | 13 | 0.190 |
Why?
| | Macrophage Activation Syndrome | 1 | 2020 | 12 | 0.190 |
Why?
| | Exotoxins | 1 | 2020 | 15 | 0.190 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 64 | 0.190 |
Why?
| | Immunotoxins | 1 | 2020 | 35 | 0.190 |
Why?
| | Multiple Myeloma | 1 | 2021 | 100 | 0.190 |
Why?
| | Cyclophosphamide | 4 | 2023 | 222 | 0.190 |
Why?
| | B-Lymphocytes | 4 | 2018 | 770 | 0.190 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 11 | 0.190 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 99 | 0.180 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 574 | 0.180 |
Why?
| | Bacterial Toxins | 1 | 2020 | 106 | 0.180 |
Why?
| | Pediatrics | 1 | 2008 | 985 | 0.180 |
Why?
| | Immunodominant Epitopes | 2 | 2012 | 27 | 0.180 |
Why?
| | Clinical Studies as Topic | 1 | 2019 | 6 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2019 | 12 | 0.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1390 | 0.170 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 16 | 0.170 |
Why?
| | Epitopes | 2 | 2018 | 443 | 0.170 |
Why?
| | Immunomodulation | 1 | 2019 | 89 | 0.170 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 15 | 0.170 |
Why?
| | History, 21st Century | 1 | 2019 | 170 | 0.170 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 454 | 0.160 |
Why?
| | Cell Membrane | 2 | 2020 | 710 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2020 | 225 | 0.160 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1094 | 0.160 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2018 | 54 | 0.160 |
Why?
| | Cryopreservation | 1 | 2019 | 99 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4596 | 0.160 |
Why?
| | History, 20th Century | 1 | 2019 | 281 | 0.160 |
Why?
| | Autoantigens | 2 | 2019 | 397 | 0.160 |
Why?
| | Membrane Proteins | 1 | 2004 | 1055 | 0.160 |
Why?
| | Protein Domains | 1 | 2019 | 212 | 0.160 |
Why?
| | Secondary Prevention | 1 | 2019 | 227 | 0.160 |
Why?
| | Graft Survival | 3 | 2011 | 504 | 0.160 |
Why?
| | Fas Ligand Protein | 2 | 2019 | 60 | 0.150 |
Why?
| | Chromatin | 2 | 2023 | 441 | 0.150 |
Why?
| | Immunophenotyping | 2 | 2020 | 278 | 0.150 |
Why?
| | Cell Division | 3 | 2012 | 776 | 0.150 |
Why?
| | Salvage Therapy | 2 | 2023 | 130 | 0.150 |
Why?
| | Inflammation Mediators | 1 | 2020 | 502 | 0.150 |
Why?
| | Retrospective Studies | 9 | 2023 | 12978 | 0.150 |
Why?
| | Cell Engineering | 1 | 2017 | 6 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 356 | 0.150 |
Why?
| | Spine | 1 | 2018 | 144 | 0.150 |
Why?
| | Lymph Nodes | 3 | 2013 | 455 | 0.150 |
Why?
| | Infant | 8 | 2018 | 8293 | 0.140 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 94 | 0.140 |
Why?
| | Stem Cell Research | 1 | 2016 | 1 | 0.140 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 187 | 0.140 |
Why?
| | Stem Cell Niche | 1 | 2016 | 43 | 0.140 |
Why?
| | Cell Proliferation | 5 | 2013 | 2275 | 0.140 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2015 | 6 | 0.140 |
Why?
| | Clone Cells | 1 | 2016 | 248 | 0.140 |
Why?
| | Gene Editing | 1 | 2016 | 63 | 0.140 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 1974 | 0.140 |
Why?
| | Prospective Studies | 5 | 2023 | 6471 | 0.140 |
Why?
| | PAX5 Transcription Factor | 1 | 2015 | 12 | 0.140 |
Why?
| | STAT Transcription Factors | 1 | 2015 | 15 | 0.130 |
Why?
| | Janus Kinases | 1 | 2015 | 14 | 0.130 |
Why?
| | Transcription Factors | 1 | 2023 | 1570 | 0.130 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2015 | 18 | 0.130 |
Why?
| | Myeloid Cells | 1 | 2016 | 128 | 0.130 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 229 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 367 | 0.130 |
Why?
| | 4-1BB Ligand | 1 | 2014 | 6 | 0.130 |
Why?
| | Cell Line | 2 | 2017 | 2707 | 0.130 |
Why?
| | Virus Replication | 1 | 2017 | 405 | 0.130 |
Why?
| | Calgranulin A | 1 | 2014 | 5 | 0.130 |
Why?
| | Calgranulin B | 1 | 2014 | 6 | 0.130 |
Why?
| | Erythrocytes | 1 | 2020 | 641 | 0.130 |
Why?
| | Growth | 1 | 1994 | 58 | 0.130 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 75 | 0.120 |
Why?
| | Growth Disorders | 1 | 1994 | 77 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2014 | 61 | 0.120 |
Why?
| | Survival Analysis | 2 | 2017 | 1267 | 0.120 |
Why?
| | Phenotype | 4 | 2019 | 3003 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2015 | 193 | 0.120 |
Why?
| | Genome | 1 | 2016 | 277 | 0.120 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 72 | 0.120 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1206 | 0.120 |
Why?
| | Attitude to Health | 2 | 2008 | 410 | 0.120 |
Why?
| | Body Height | 1 | 1994 | 187 | 0.120 |
Why?
| | Incidence | 2 | 2018 | 2424 | 0.120 |
Why?
| | Transduction, Genetic | 3 | 2019 | 116 | 0.120 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2014 | 158 | 0.120 |
Why?
| | fas Receptor | 2 | 2019 | 98 | 0.110 |
Why?
| | Animals, Congenic | 1 | 2012 | 10 | 0.110 |
Why?
| | Radiation Chimera | 1 | 2012 | 31 | 0.110 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2012 | 61 | 0.110 |
Why?
| | Proteins | 1 | 2019 | 938 | 0.110 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 56 | 0.110 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2012 | 41 | 0.110 |
Why?
| | Tumor Burden | 1 | 2013 | 274 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 248 | 0.110 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2012 | 58 | 0.110 |
Why?
| | Treatment Failure | 2 | 2014 | 341 | 0.110 |
Why?
| | HIV Infections | 3 | 2008 | 2459 | 0.110 |
Why?
| | Brain Neoplasms | 2 | 2011 | 1022 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 539 | 0.110 |
Why?
| | Antigen-Presenting Cells | 2 | 2010 | 156 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2015 | 688 | 0.100 |
Why?
| | Chemokines | 1 | 2013 | 230 | 0.100 |
Why?
| | Body Weight | 2 | 2002 | 934 | 0.100 |
Why?
| | Blood Component Removal | 1 | 2011 | 34 | 0.100 |
Why?
| | Methoxsalen | 1 | 2011 | 4 | 0.100 |
Why?
| | Spleen | 2 | 2011 | 510 | 0.100 |
Why?
| | Adenovirus Infections, Human | 1 | 2010 | 14 | 0.100 |
Why?
| | Cytosine | 1 | 2010 | 46 | 0.100 |
Why?
| | Alleles | 1 | 2013 | 832 | 0.100 |
Why?
| | Blood | 1 | 2011 | 100 | 0.090 |
Why?
| | Antiviral Agents | 2 | 2018 | 654 | 0.090 |
Why?
| | Organophosphonates | 1 | 2010 | 94 | 0.090 |
Why?
| | Models, Biological | 2 | 2009 | 1715 | 0.090 |
Why?
| | Acute Disease | 3 | 2023 | 940 | 0.090 |
Why?
| | Sarcoma | 1 | 2011 | 137 | 0.090 |
Why?
| | Transplantation Immunology | 1 | 2009 | 31 | 0.090 |
Why?
| | CD4 Lymphocyte Count | 3 | 2008 | 267 | 0.090 |
Why?
| | Lymphocyte Count | 2 | 2017 | 136 | 0.090 |
Why?
| | Intestinal Neoplasms | 1 | 2009 | 23 | 0.090 |
Why?
| | Hematopoietic System | 1 | 2008 | 7 | 0.080 |
Why?
| | Virus Diseases | 1 | 2011 | 198 | 0.080 |
Why?
| | Interleukin-12 | 1 | 2009 | 110 | 0.080 |
Why?
| | Sibling Relations | 1 | 2008 | 11 | 0.080 |
Why?
| | Substrate Specificity | 1 | 2009 | 371 | 0.080 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2008 | 43 | 0.080 |
Why?
| | Biomarkers | 2 | 2016 | 3588 | 0.080 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 76 | 0.080 |
Why?
| | Ultraviolet Rays | 1 | 2011 | 381 | 0.080 |
Why?
| | Psychology | 1 | 2008 | 84 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2014 | 762 | 0.080 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 870 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 874 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2014 | 4077 | 0.070 |
Why?
| | Immune Tolerance | 2 | 2010 | 334 | 0.070 |
Why?
| | Recombinant Proteins | 5 | 2011 | 1308 | 0.070 |
Why?
| | Brain | 1 | 2018 | 2490 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1012 | 0.060 |
Why?
| | Immunologic Surveillance | 1 | 2004 | 19 | 0.060 |
Why?
| | United States | 4 | 2018 | 12555 | 0.060 |
Why?
| | Hemostasis | 1 | 2004 | 70 | 0.060 |
Why?
| | Obesity | 2 | 2022 | 2746 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2023 | 22 | 0.060 |
Why?
| | CD3 Complex | 2 | 2017 | 92 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 398 | 0.060 |
Why?
| | Body Mass Index | 1 | 2009 | 2092 | 0.050 |
Why?
| | Histocompatibility Testing | 2 | 2014 | 123 | 0.050 |
Why?
| | Cohort Studies | 3 | 2014 | 5116 | 0.050 |
Why?
| | United Kingdom | 2 | 2009 | 236 | 0.050 |
Why?
| | Protein Binding | 2 | 2019 | 1975 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 167 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 333 | 0.050 |
Why?
| | Thymectomy | 1 | 2001 | 15 | 0.050 |
Why?
| | HIV Protease Inhibitors | 1 | 2001 | 64 | 0.050 |
Why?
| | Middle Aged | 6 | 2021 | 27617 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2001 | 58 | 0.050 |
Why?
| | Ritonavir | 1 | 2001 | 70 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2011 | 2235 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2021 | 141 | 0.050 |
Why?
| | Lymphocytes | 1 | 2002 | 347 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1047 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2020 | 287 | 0.040 |
Why?
| | Hematopoiesis | 2 | 2016 | 175 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2019 | 19 | 0.040 |
Why?
| | Subcutaneous Emphysema | 1 | 1999 | 1 | 0.040 |
Why?
| | Aged | 5 | 2021 | 19657 | 0.040 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2019 | 16 | 0.040 |
Why?
| | Single-Chain Antibodies | 1 | 2019 | 14 | 0.040 |
Why?
| | Vulva | 1 | 1999 | 24 | 0.040 |
Why?
| | K562 Cells | 1 | 2019 | 73 | 0.040 |
Why?
| | Mice, Nude | 1 | 2001 | 663 | 0.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1999 | 20 | 0.040 |
Why?
| | Age Factors | 3 | 2011 | 2995 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2023 | 1753 | 0.040 |
Why?
| | Up-Regulation | 3 | 2008 | 872 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 262 | 0.040 |
Why?
| | Transgenes | 1 | 2019 | 174 | 0.040 |
Why?
| | Hallucinations | 1 | 2018 | 29 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2018 | 21 | 0.040 |
Why?
| | Confusion | 1 | 2018 | 26 | 0.040 |
Why?
| | Risk Factors | 4 | 2018 | 9000 | 0.040 |
Why?
| | Immunization | 1 | 2001 | 412 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 35 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 115 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| | Weight Loss | 1 | 2002 | 655 | 0.040 |
Why?
| | Steroids | 1 | 2018 | 153 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 298 | 0.040 |
Why?
| | Gene Order | 1 | 2017 | 28 | 0.040 |
Why?
| | Graft Rejection | 1 | 2001 | 555 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 191 | 0.040 |
Why?
| | Advisory Committees | 1 | 2018 | 212 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 356 | 0.040 |
Why?
| | Transfection | 1 | 2019 | 888 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2019 | 625 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2018 | 649 | 0.040 |
Why?
| | Medical Oncology | 1 | 2018 | 229 | 0.040 |
Why?
| | Cell Cycle | 1 | 2019 | 550 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 4708 | 0.030 |
Why?
| | Protein Engineering | 1 | 2017 | 107 | 0.030 |
Why?
| | Time Factors | 4 | 2008 | 6412 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2016 | 44 | 0.030 |
Why?
| | Research Subjects | 1 | 2016 | 40 | 0.030 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2015 | 20 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2017 | 267 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 5255 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 443 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 333 | 0.030 |
Why?
| | CD28 Antigens | 1 | 2015 | 46 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 2874 | 0.030 |
Why?
| | Transplantation Chimera | 1 | 2014 | 51 | 0.030 |
Why?
| | Exons | 1 | 2015 | 307 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 60 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 703 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2513 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 416 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 245 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 756 | 0.030 |
Why?
| | Reference Values | 1 | 1994 | 774 | 0.030 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 336 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 755 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 371 | 0.030 |
Why?
| | Vidarabine | 1 | 2012 | 27 | 0.030 |
Why?
| | Aging | 1 | 2002 | 1670 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2014 | 224 | 0.030 |
Why?
| | Vincristine | 1 | 2012 | 99 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2014 | 749 | 0.030 |
Why?
| | Etoposide | 1 | 2012 | 149 | 0.030 |
Why?
| | Administration, Oral | 1 | 2014 | 756 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 82 | 0.030 |
Why?
| | Rituximab | 1 | 2012 | 155 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 235 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 302 | 0.020 |
Why?
| | Bacteremia | 1 | 2011 | 161 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 45 | 0.020 |
Why?
| | Bone Neoplasms | 1 | 2012 | 199 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 612 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2009 | 42 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1323 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 842 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2008 | 71 | 0.020 |
Why?
| | Risk | 1 | 2011 | 853 | 0.020 |
Why?
| | Leukocytes | 1 | 2010 | 290 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2657 | 0.020 |
Why?
| | Mass Screening | 1 | 1994 | 1052 | 0.020 |
Why?
| | Cell Separation | 1 | 2008 | 296 | 0.020 |
Why?
| | HLA Antigens | 1 | 2008 | 230 | 0.020 |
Why?
| | Macaca fascicularis | 1 | 2007 | 53 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 226 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3174 | 0.020 |
Why?
| | HIV | 1 | 2008 | 210 | 0.020 |
Why?
| | Cell Polarity | 1 | 2007 | 133 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2009 | 286 | 0.020 |
Why?
| | Body Composition | 1 | 2009 | 653 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 182 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 273 | 0.020 |
Why?
| | Annexin A5 | 1 | 2004 | 24 | 0.020 |
Why?
| | Adiposity | 1 | 2009 | 516 | 0.020 |
Why?
| | Interleukins | 1 | 2006 | 242 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 681 | 0.020 |
Why?
| | Coloring Agents | 1 | 2004 | 73 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 108 | 0.020 |
Why?
| | Stromal Cells | 1 | 2004 | 102 | 0.020 |
Why?
| | Macaca mulatta | 1 | 2004 | 153 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1795 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2004 | 334 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1868 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 745 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 622 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2001 | 17 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 595 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2001 | 76 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1624 | 0.010 |
Why?
| | Colon | 1 | 2002 | 238 | 0.010 |
Why?
| | Pubic Bone | 1 | 1999 | 4 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3057 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1171 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 1999 | 32 | 0.010 |
Why?
| | Hyperbaric Oxygenation | 1 | 1999 | 39 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1882 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 1798 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1284 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 4552 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1816 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2436 | 0.010 |
Why?
|
|
Fry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|